Biomarker detection firm Quanterix reaffirms 2026 revenue guidance

Quanterix

06/05/2026 21:13

Overview

U.S. biomarker detection firm's Q1 revenue rose 20% yr/yr to $36.4 mln

Adjusted EBITDA loss narrowed to $9.8 mln from $11.3 mln a year ago

Company says Alzheimer's diagnostics business continues rapid growth, with key milestones ahead

Outlook

Quanterix reaffirms 2026 revenue guidance of $169 mln to $174 mln

Company expects 2026 GAAP gross margin of 41%-45%, adjusted gross margin of 49%-53%

Quanterix expects to achieve cash flow breakeven in H2 2026 and end year with $100 mln cash, no debt

Result Drivers

ALZHEIMER'S DIAGNOSTICS - Co said rapid growth in its Alzheimer's diagnostics business contributed to Q1 performance

COMMERCIAL INITIATIVES - Co said it is prioritizing investment to drive commercial effectiveness and improve operating results

COST SYNERGIES - Co said it has captured cost synergies from the Akoya acquisition, aiding progress toward cash flow breakeven

Company press release: ID:nBw4jVVSta

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Revenue
$25.48 mln
Q1 Net Income
-$17.54 mln
Q1 Basic EPS
-$0.37
Q1 Gross Profit
$15.57 mln
Q1 Operating Expenses
$56.93 mln
Q1 Loss from operations
$41.36 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Quanterix Corp is $7.00, about 112.1% above its May 5 closing price of $3.30

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)